{
    "relation": [
        [
            "",
            "Stage 1: Insulin Aspart",
            "Stage 1: Insulin Aspart-rHuPH20",
            "Stage 3: Insulin Aspart",
            "Stage 3: Insulin Aspart + rHuPH20"
        ],
        [
            "Description",
            "Participants received 0.15 units per kilogram (U/kg) insulin aspart, administered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4 or 5-8), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4 of Period 1 or Days 6 and 8 of Period 2.",
            "Participants received 0.15 units per kilogram (U/kg) insulin aspart and 5 micrograms per milliliter (\u03bcg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) administered together as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4 or 5-8), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4 of Period 1 or Days 6 and 8 of Period 2.",
            "Participants received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5 or 6-10), including during a 6-hour (hr) euglycemic clamp on Days 2, 3 and 5 of Period 1 or Days 7, 8, and 10 of Period 2. On Day 2 or Day 7 only, a sham injection was administered 2.5 hr prior to the 6-hr euglycemic clamp.",
            "Participants received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5 or 6-10), including during a 6-hour (hr) euglycemic clamp on Days 2, 3, and 5 of Period 1 or Days 7, 8, and 10 of Period 2. On Day 2 or Day 7 only, a 1-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (\u03bcg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the 6-hr euglycemic clamp."
        ]
    ],
    "pageTitle": "Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01275131?sect=X30156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042986022.41/warc/CC-MAIN-20150728002306-00243-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 873660599,
    "recordOffset": 873641632,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Insulin aspart Drug: Recombinant human hyaluronidase PH20 (rHuPH20) Interventions: Type 1 Diabetes Mellitus Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Pharmacokinetics/Dynamics\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Crossover\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Caregiver,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Basic\u00a0Science Study Design: Interventional Study Type: Results First Received: June 26, 2014 \u00a0",
    "textAfterTable": "Participant Flow for 3 periods Period 1: \u00a0 Period 1 \u00a0 \u00a0 Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20 \u00a0 \u00a0 Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin Aspart \u00a0 \u00a0 Stage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20 \u00a0 \u00a0 Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin Aspart \u00a0 STARTED \u00a0 \u00a0 11 \u00a0 \u00a0 9 \u00a0 \u00a0 13 \u00a0 \u00a0 12 \u00a0 Received at Least One Dose of Study Drug \u00a0 \u00a0 11 \u00a0 \u00a0 9 \u00a0 \u00a0 13 \u00a0 \u00a0 12 \u00a0 COMPLETED \u00a0 \u00a0 9 \u00a0 \u00a0 9 \u00a0 \u00a0 10 \u00a0 \u00a0 10 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}